Status:
RECRUITING
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Lead Sponsor:
Eli Lilly and Company
Conditions:
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib....
Eligibility Criteria
Inclusion
- Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.
Exclusion
- Exclusion criteria are defined in each ISA.
Key Trial Info
Start Date :
May 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2032
Estimated Enrollment :
787 Patients enrolled
Trial Details
Trial ID
NCT06876649
Start Date
May 20 2025
End Date
December 1 2032
Last Update
December 16 2025
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Specialists, LLC
Jacksonville, Florida, United States, 32256
2
Sylvester Comprehensive Cancer Center
Miami, Florida, United States, 33136-1002
3
Florida Cancer Specialists
Sarasota, Florida, United States, 34232-6422
4
The Emory Clinic
Atlanta, Georgia, United States, 30322-1013